BidaskClub Lowers LeMaitre Vascular (LMAT) to Sell

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Tuesday, October 31st. Stifel Nicolaus reissued a “buy” rating on shares of LeMaitre Vascular in a report on Sunday, October 29th. Canaccord Genuity decreased their price objective on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating for the company in a report on Friday, October 27th. Benchmark downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Finally, First Analysis downgraded LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price objective for the company. in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $32.20.

LeMaitre Vascular (LMAT) traded down $0.16 during mid-day trading on Friday, hitting $32.77. The stock had a trading volume of 140,071 shares, compared to its average volume of 167,760. The firm has a market capitalization of $634.39, a P/E ratio of 42.77, a P/E/G ratio of 2.61 and a beta of 0.55. LeMaitre Vascular has a 1-year low of $19.82 and a 1-year high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The business had revenue of $24.80 million during the quarter, compared to the consensus estimate of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 earnings per share. equities analysts anticipate that LeMaitre Vascular will post 0.84 earnings per share for the current fiscal year.

In related news, insider David B. Roberts sold 4,123 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the completion of the sale, the insider now directly owns 24,482 shares of the company’s stock, valued at $786,851.48. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 23.70% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA lifted its holdings in shares of LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 3,716 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after purchasing an additional 2,667 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of LeMaitre Vascular during the second quarter worth $137,000. LS Investment Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 41.8% during the third quarter. LS Investment Advisors LLC now owns 4,510 shares of the medical instruments supplier’s stock worth $169,000 after purchasing an additional 1,330 shares during the period. Finally, Royce & Associates LP acquired a new stake in shares of LeMaitre Vascular during the second quarter worth $156,000. 69.43% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers LeMaitre Vascular (LMAT) to Sell” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/02/bidaskclub-lowers-lemaitre-vascular-lmat-to-sell.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply